The Value of Brain Structural Magnetic Resonance Imaging Combined with APOE--<i>ε</i>4 Genotype in Early Diagnosis and Disease Progression of Senile Vascular Cognitive Impairment No Dementia

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td class="align_left">Features</td><td class="align_center">NC group (<i>n</i> = 50)</td><td class="align_center">VCIND group (<i>n</i> = 130)</td><td class="align_center"><i>t/z</i></td><td class="align_center"><i>P</i></td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td class="align_left">Clinical Dementia Rating (CDR）</td><td class="align_center">8 (7–9)</td><td class="align_center">12 (11–14)</td><td class="align_center">8.993</td><td class="align_center">≤0.001</td></tr><tr><td class="align_left">Activity of Daily Living Scale (ADL)</td><td class="align_center">13 (10–16)</td><td class="align_center">13.5 (12–16)</td><td class="align_center">1.924</td><td class="align_center">0.054</td></tr><tr><td class="align_left">Montreal Cognitive Assessment (MoCA)</td><td class="align_center">19.74 ± 2.93</td><td class="align_center">15.89 ± 3.09</td><td class="align_center">7.589</td><td class="align_center">≤0.001</td></tr><tr><td class="align_left">Elderly Cognitive Abilities Screening Instrument (CASI)</td><td class="align_center">24 (23–25)</td><td class="align_center">17 (15–19)</td><td class="align_center">9.783</td><td class="align_center">≤0.001</td></tr><tr><td class="align_left">Hamilton Rating Scale For Depression (HAMD)</td><td class="align_center">9 (6–10)</td><td class="align_center">16 (12–18)</td><td class="align_center">8.860</td><td class="align_center">≤0.001</td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>Values are mean ± SD or median (P25, P75). NC, normal control; VCIND, vascular cognitive impairment no dementia.<br/></div></td></tr></table>

<div>Comparison of cognitive psychology assessment between the two groups of patients.</div>

Contrast Media & Molecular Imaging

tab3

Table 3

Table 3: The Value of Brain Structural Magnetic Resonance Imaging Combined with APOE--<i>ε</i>4 Genotype in Early Diagnosis and Disease Progression of Senile Vascular Cognitive Impairment No Dementia 

Table 3 | The Value of Brain Structural Magnetic Resonance Imaging Combined with APOE--ε4 Genotype in Early Diagnosis and Disease Progression of Senile Vascular Cognitive Impairment No Dementia 